Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) Chronic lymphocytic leukemia (CLL) is a heterogeneous disease characterized by the accumulation of mature B cells incapable of undergoing apoptosis. Constitutively activated signaling proteins, such as phosphatidylinositol 3 (PI3)-kinase and Protein kinases C (PKCs), contribute to the defect of the programmed cell death. It has also become increasingly evident that a distinct compartment of proliferative cells account for the progression of the disease. Such dividing B-CLL cells can be found in the so-called proliferation centers in the spleen and bone marrow of CLL patients, although the underlying signals that drive cells into the cell cycle are not well defined. While disease progression is dependent on proliferative B-CLL cells rather than on G1-arrested cells, therapies aimed at blocking cell cycle progression seem to be a new and striking approach to the treatment of CLL patients.
The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells
Leflunomide (SU101 or HWA 486) is a novel isoaxzole derivate that in vivo becomes rapidly converted to its active metabolite A77 1726. Because the drug has an antiproliferative effect on human T cells, it was introduced in the treatment of rheumatoid arthritis and other autoimmune diseases. Leflunomide specifically inhibits the activity of dihydro-orotate dehydrogenase (DHODH) in a non-competitive manner. 1 DHODH is the rate-limiting enzyme in the de novo biosynthesis of pyrimidines. While its antiproliferative effect on lymphocytes and mononuclear cells is completely reversible by exogenous uridine, blockade of DHODH is considered to be the main mode of action. However, other targets have been defined and may contribute to the inhibitory effects of Leflunomide regardless of the availability of pyrimidines: Leflunomide inhibits platelet-derived growth factor receptor-mediated signal transduction including tyrosine phosphorylation and cell cycle progression. Importantly, doses required to block tyrosine phosphorylation are approximately 10-to 100-fold higher than those needed to block pyrimidine synthesis. 2 However, some reports have pointed to other potential effects of Leflunomide, including downregulation of cytokine production and decreased expression of cytokine receptors.
Because activated lymphocytes have a high demand for pyrimidines during proliferation, we hypothesized that Leflunomide potentially could block cell cycle progression of malignant B-CLL cells and therefore be a potential new drug in the treatment of the disease.
Stimulation of CLL cells with CpG oligonucleotides, such as DSP30, and interleukin-2 (IL-2) can rapidly and robustly induce cell proliferation in B-CLL cells in the absence of 'contaminating T cells'. DSP30 is a single stranded, phosphorothioate stabilized oligonucleotide (n ¼ 27) which carries an unmethylated CpG motif. Using such an in vitro model for B-CLL cell proliferation, we tested whether Leflunomide (or its active metabolite Teriflunomide) can block cell growth of purified malignant B cells. DSP30/IL-2-stimulated B-CLL cells were cultured in the presence of increasing doses of Teriflunomide (range 0.5-100 mM) and cell viability was determined by an MTT assay after 72 h of culturing cells. (Cells were purified and cultured as described previously.) 3, 4 We observed that Teriflunomide induced a decrease of viable cells in a dose-dependent manner. Importantly, a dose of 10 mM Teriflunomide was sufficient to decrease cell proliferation compared to DSP30/IL-2-stimulated cells in the absence of the inhibitor (P ¼ 1.36 Â 10 À7 , Figure 1a ). Such doses are below those needed to achieve similar effects on peripheral blood mononuclear cells of normal donors, indicating that CLL cells are very sensitive to Teriflunomide (data not shown). However, at high concentrations, the cell inhibitory effects were similar to those achieved by rapamycin treatment.
To confirm our hypothesis that the decrease in cell viability was related to a cell cycle arrest, cells were pulsed with bromodeoxyuridine (BrdU) for 4 h and co-stained with CD19. In the presence of Teriflunomide, cycling CLL cells incorporate significantly less BrdU than when stimulated with DSP30/IL-2 alone. Conclusively, Teriflunomide is a potent cell cycle inhibitor in activated CLL cells ( Figure 1b ). As shown in Supplementary Table 1, the antiproliferative effect of Teriflunomide on activated B-CLL cells was not related to disease stage, ZAP70 expression or number of previous therapies.
We next sought to investigate the effects of Leflunomide on the expression of cyclins and cyclin-dependent kinases (cdks). To this end, cells were stimulated for 72 h with DSP30 and IL-2 in the presence or absence of Teriflunomide. Addition of Teriflunomide blocked the upregulation of cyclin D3 and cyclin A, whereas the expression of cyclin D2 or cyclin E was not affected (Figure 2a ). The reduced expression of cyclin D3 also prevented a hyperphosphorylation of retinoblastoma (Rb). Accordingly, downregulation of the cell cycle inhibitor p27 was partially blocked by Teriflunomide after 24 h, but further decreased over the time to levels comparable to DSP30/IL-2 stimulation alone. It is worthwhile mentioning here that the loss of p27 is insufficient to promote cell proliferation of B-CLL cells unless D-cyclins are expressed. 5 To further test whether reduced levels of cyclin D3 expression impair cdk2 activity, cdk2 complexes were immuno-precipitated from cells stimulated with or without Teriflunomide and an in vitro kinase assay was performed using histone H1 as a substrate. After 48 h, cdk2 complexes isolated from cells co-cultured with Teriflunomide completely failed to phosphorylate histone H1, in contrast to cells stimulated with DSP30 and IL-2 alone (Figure 2b ). Cdk2 activity partly recovered after 72 h according to a small subset of cycling cells after 72 h of treatment (Figure 1b) .
To characterize the toxic effects of Teriflunomide on G1-arrested cells, we also monitored its ability to induce apoptosis in B-CLL cells. Interestingly, we observed marked differences between ZAP70-positive and -negative cells: Teriflunomide treatment of highly aggressive, ZAP70-positive cells induced apoptosis in G1-arrested cells, whereas it failed to induce cell death in ZAP70-negative cells (Figure 3a) . Teriflunomide treatment rather seemed to reduce spontaneous apoptosis, although no statistical significance was observed (P ¼ 0.22). The proapoptotic effect of Teriflunomide on ZAP70-positive cells was restricted to arrested cells. B-CLL cells of this subgroup were protected from Teriflunomide-induced cell death by DSP30/IL-2 activation (Figure 3b) . Therefore, we assume that 
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Teriflunomide interferes with different pathways involved either in cell proliferation of activated (ZAP70-positive and -negative) CLL cells or in an apoptosis defect of arrested, ZAP70-positive CLL cells in the peripheral blood.
To test whether the antiproliferative effect of Teriflunomide on CLL cells is mediated by an inhibition of DHODH and a subsequent depletion of uridine, cycling B-CLL cells were cultured in the presence of Teriflunomide and an excess of exogenous uridine. Surprisingly, the addition of 100 mM urindine was unable to antagonize the antiproliferative effect of Teriflumonide on activated B-CLL cells (Supplementary Figure 1) .
We therefore asked whether Teriflunomide directly interferes with the stimulatory effects of CpG oligonucleotides and IL-2. Stimulation of B-CLL cells with DSP30 induces cell proliferation and increases the expression of co-stimulatory molecules. We have demonstrated that co-stimulation of cells with IL-2 has a synergistic effect with CpG-ODN, based on the induction of high-affinity IL-2 receptors. As Leflunomide has been shown to impair IL-2 signaling through downregulation of IL-2 receptors, 6 we analyzed whether Teriflunomide blocked the upregulation of CD25 on CLL cells. B-CLL cells were stimulated with DSP30 and IL-2 in the presence of Teriflunomide and expression of the IL-2R a-chain was analyzed by flow cytometry. Upon DSP30/IL-2 stimulation, surface expression of high-affinity IL-2 receptors, CD25 respectively, was not diminished due to Teriflunomide treatment (Supplementary Figure 2) . In line with these data, it is worthwhile to mention that the cell cycle inhibitory effect of Teriflunomide is not restricted to DSP30/IL-2-stimulated cells but can be observed in cycling B-CLL cells activated by TPA and PHA, which have no effect on the expression of CD25 (data not shown).
In summary, we discovered that the immunomodulatory drug Leflunomide potently blocks cell proliferation of malignant B-CLL cells, irrespective of their ZAP70 status. Because disease progression of CLL most likely arises from niches of proliferating B-CLL cells in the bone marrow and spleen, targeting those cycling cells might be a promising approach to control or even cure CLL. However, the mode of action of Leflunomide on B-CLL cells seems to be distinct in normal B-and T-lymphocytes. Here, the antiproliferative effect of Leflunomide is linked to a non-competitive, reversible inhibition of DHODH and can be reversed by an exogenous supply of UTP. Because this is not the case for B-CLL cells, targets other than DHODH must mediate growth inhibition. In case of B-CLL, the antiproliferative effects of Teriflunomide on activated cells may be related to its properties to block tyrosine phosphorylation. Tyrosine- phosphorylation is ubiquitously used to control the activity of numerous intracellular enzymes, which allows rapidly switching proteins from an inactive state to an active state and vice versa. In B-CLL, cell proliferation strongly depends on the function of the ribosomal s6 kinase (p70S6K).
3 p70S6K is a highly conserved protein kinase downstream of the mammalian target of rapamycin (mTOR) and regulates the translation of mRNAs encoding proteins of the translational apparatus. The activation of p70S6 kinase requires phosphorylation of several threonine and serine sites. mTOR activates p70S6 kinase through phosphorylation on threonine 389. We observed that threonine phosphorylation of p70S6 kinase was readily detected 3 h after treatment with DSP30 and IL-2, whereas co-treatment of cells with Teriflumomide significantly diminished the phosphorylation of p70S6 kinase (data not shown). Because Leflunomide is known to inhibit tyrosine phosphorylation but not serine or threonine phosphorylation, the inhibitory effect on threonine-389 phosphorylation is unlikely to be a direct effect of Leflunomide. We hypothesized that Leflunomide acts upstream of mTOR in activated B-CLL cells by interrupting signal-transduction pathways leading to mTOR activation.
In addition to its growth inhibitory effect on activated CLL cells, Teriflunomide induces apoptosis in peripheral B-CLL cells arrested in G1 (Figure 3 ). This effect is restricted to ZAP70-positive cells. Although currently we do not understand the differences of apoptosis induction between ZAP70-positive and -negative cells, we believe that the proapoptotic response of B-CLL cells to Teriflunomide is of clinical importance for this subgroup of patients with a poor prognosis. An increasing body of evidence has demonstrated that the apoptotic defect of B-CLL cells depends on the constitutive activation of several signaling pathways; among these, PI3-kinase/PKC-d and nuclear factor-kappa B are important. 4 In light of these aberrant signaling pathways, it is tempting to speculate that Leflunomide interferes with constitutively activated signaling pathways through its capacity to inhibit tyrosine phosphorylation, thereby inducing apoptosis in this subset of B-CLL cells. We assume that pro-mitotic factors, such as DSP30/IL-2, provide antiapoptotic signals, which prevent Leflunomide from inducing apoptosis in activated, ZAP70-positive B-CLL cells.
In conclusion, we identified that the immunomodulatory drug Leflunomide not only inhibits cell cycle progression of activated CLL cells but also induces apoptosis in ZAP70-positive, G1-arrested cells. These properties of Leflunomide might be an advantage over rapamycin, another cell cycle inhibitor, which lacks proapoptotic effects on quiescent B-CLL cells. 3 Extensive experience from clinical trials with Leflunomide in patients with rheumatoid arthritis has demonstrated that it is well tolerated, with only mild to moderate side effects. In light of its antileukemic effects on different cellular compartments, particularly in CLL patients with an unfavorable prognosis, Leflunomide is a promising new candidate for the treatment of CLL patients. I Ringshausen, M Oelsner, C Bogner, C Peschel and T Decker 3rd Department of Medicine, Technical University of Munich, Munich, Germany E-mail: i.ringshausen@lrz.tum.de Accumulating evidence indicates that hypermethylation of CpG islands (CGIs) is a prevalent molecular event in human cancers, and the list of genes affected continues to grow. When a normally unmethylated CGI located within the promoter or other regulatory region of a gene becomes methylated in cancer cells, the outcome is frequently a loss of expression of adjacent genes. As a step toward a better understanding of this widespread phenomenon, our laboratory utilized a microarray containing 47K CpG loci for DNA methylation analysis to survey the genome-wide methylation present in a subgroup of non-Hodgkin's lymphomas, the small B-cell lymphomas (SBCLs) 1 and acute lymphoblastic leukemia (ALL). 2 These studies identified several genes and loci in which differential methylation was present among histological classes, thus showing that aberrant methylation is a nonrandom event in these malignancies. Several models have been proposed to explain the presence of the nonrandom patterns of methylation in cancer. The first postulates that a genetic event responsible for the activation of an oncogene could trigger the initiation of tumor development through dysregulation of the DNA methylation machinery. A second postulated model suggests that some DNA sequences are readily methylatable while others are not. For example, sequences could be protected from methylation by the presence of DNA binding proteins such as transcription factors, which prevent the methylation machinery from gaining physical access to DNA. Conversely, sequences that are readily methylated may contain specific DNA binding sequence motifs that aid in the
